• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diagnostic and therapeutic endoscopy >Angioscopic Evaluation of Stabilizing Effects of Bezafibrate on Coronary Plaques in Patients With Coronary Artery Disease
【24h】

Angioscopic Evaluation of Stabilizing Effects of Bezafibrate on Coronary Plaques in Patients With Coronary Artery Disease

机译：苯扎贝特对冠状动脉疾病患者冠状斑块稳定作用的血管造影评价

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundSince long-term administrations of anti-hyperlipidemicagents result in reduction in % stenosis or increase inminimum lumen diameter (MLD) of stenotic coronarysegments, it is generally believed that anti-hyperlipidemic agentsstabilize vulnerable coronary plaques. However, recent pathologicand angioscopic studies revealed that vulnerability of coronaryplaques is not related to severity of stenosis and the rims ratherthan top of the plaques disrupt, and therefore, angiography is notadequate for evaluation of vulnerability.Angioscopyenables macroscopic pathological evaluation of the coronary plaques.Therefore, we carried out a prospective angioscopic open trial for evaluation of thestabilizing effects of bezafibrate on coronary plaques.MethodsFrom April, 1997 to December, 1998, 24 patients underwentcoronary angioscopy of the plaques in the non-targeted vesselsduring coronary interventions and 6 months later. The patientswere divided into control (10 patients, 14 plaques) andbezafibrat (14 patients, 21 plaques) groups. Oraladministration of bezafibrate (Bezatol SR, 400mg/day) wasstarted immediately after the interventions and was continued for6 months. The vulnerability score was determined based onangioscopic characteristics of plaques and it was compared beforeand 6 months later.ResultsSix months later, vulnerability score was reduced(from 1.6 to 0.8;p< 0.05) in bezafibrate group andunchanged (from 1.4 to 1.3; NS) in control group. Inbezafibrate group, the changes in vulnerability score was notcorrelated with those in % stenosis or MLD.ConclusionThe results indicate that bezafibrate can stabilize coronary plaques.
机译：背景技术由于长期服用抗高血脂药会导致狭窄的冠状动脉段狭窄百分比降低或最小管腔直径（MLD）的增加，因此，人们普遍认为抗高血脂药可稳定脆弱的冠状动脉斑块。但是，最近的病理学和血管镜检查表明，冠状动脉斑块的易损性与狭窄的严重程度无关，并且轮缘而不是斑块的顶部破裂，因此血管造影不足以评估其易损性。我们进行了一项前瞻性血管镜开放试验，以评估苯扎贝特对冠状动脉斑块的稳定作用。方法从1997年4月至1998年12月，在冠状动脉介入治疗期间和6个月后，对24例患者进行了非靶向性冠状动脉斑块血管造影。将患者分为对照组（10例，14个斑块）和贝扎非特（14例，21个斑块）组。干预后立即开始口服苯扎贝特（Bezatol SR，400mg /天），并持续6个月。结果：根据斑块的血管镜特征确定脆弱性评分，并在前后六个月进行比较。结果六个月后，苯扎贝特组的脆弱性评分从1.6降低到0.8; p <0.05，NS从1.4改变为1.3。控制组。 Inbezafibrate组的脆弱性得分的变化与狭窄程度或MLD无关。结论：bezafibrate可以稳定冠状动脉斑块。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号